Skip to content
value.today
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc.

TCRX
$14 Mmarket cap on Oct 29, 2026-95.0% since Jan 2024
Compare
World rank
#25,329
Revenue
$10 M
For year ending December-2025
Net income
$-130 M
-1257.5% margin
SEC filing
Employees
142
As of February 27, 2026
SEC filing

TScan Therapeutics, Inc. in brief

TScan Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Waltham, Massachusetts, USA. Its market value was $14 M on 29 October 2026, which makes it the 25,329th largest listed company in the world and the 4,234th largest in the USA on this site. In the year to December 2025 it had sales of $10 M and a net loss of $130 M. It employs about 142 people and Gavin MacBeath is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol TCRX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About TScan Therapeutics, Inc.

We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The product is designed to eliminate residual disease and promote complete donor chimerism, thereby preventing relapse. TSC-101 targets HA-2, an antigen that is present on all blood cells, malignant or benign, in patients with the HLA type A*02:01. We are currently conducting a Phase 1 clinical study of TSC-101 (the ALLOHA™ trial, NCT05473910) and during the fourth quarter of 2025, following a productive End-of-Phase meeting with the U.S. Food and Drug Administration (FDA), we reached agreement on a registrational path forward for the TSC-101 program as a potential treatment for patients with AML and MDS. The pivotal study will mirror our ongoing Phase 1 ALLOHA study, using a biologically-assigned (genetically randomized) control arm to support relapse-free survival as the primary endpoint.

From the company's annual report filed with the US SEC: read the report

TScan Therapeutics, Inc. timeline

3 events, 2019–2023
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 19 July 2021; shares registered for exchange trading on 13 July 2021.
  5. 2023
  6. 💰
    Record revenue of $21 million
    FY2023, the highest of the 5 years on record.

Events of TScan Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$73 M$146 M$219 M$292 M2023202420252026

World rank over time

▼ down 3,164 places since 2022
2022-01-07: #22171#22,17120222022-12-25: #26724#26,72420222023-07-30: #21699#21,69920232024-01-05: #16348#16,34820242026-03-08: #10623#10,62320262026-08-01: #19496#19,49620262026-10-14: #25210#25,21020262026-10-29: #25335#25,3352026

Rank in USA: #4,341 (Jan 2022) · #4,992 (Dec 2022) · #4,229 (Jul 2023) · #3,019 (Jan 2024) · #2,075 (Mar 2026) · #3,742 (Aug 2026) · #4,225 (Oct 2026) · #4,236 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
2.6×
Price / book
0.1×
Free cash flow yield
-1030.5%
Net margin (TTM)
-2221.8%
Operating margin
-1316.0%
Return on equity
-93.5%
Liabilities / assets
46.2%
Net debt
$-120M
Revenue growth
+266.0%
R&D / revenue
1106.1%
Revenue per employee
$73 K
Profit per employee
$-914 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-26M—FY20Fiscal year ending Dec 2021: revenue $10M, net income $-49M$10MFY21Fiscal year ending Dec 2022: revenue $14M, net income $-66M$14MFY22Fiscal year ending Dec 2023: revenue $21M, net income $-89M$21MFY23Fiscal year ending Dec 2024: revenue $3M, net income $-128M$3MFY24Fiscal year ending Dec 2025: revenue $10M, net income $-130M$10MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$10M+266.0%$-136M$-130M-1257.5%
Dec 2024$3M-86.6%$-135M$-128M-4521.3%
Dec 2023$21M+55.5%$-93M$-89M-423.8%
Dec 2022$14M+33.5%$-67M$-66M-489.1%
Dec 2021$10M—$-49M$-49M-479.5%
Dec 2020——$-26M$-26M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-135M$4M$-140M$-1.00—
Dec 2024$-111M$4M$-115M$-1.14—
Dec 2023$-61M$3M$-65M$-1.36—
Dec 2022$-67M$4M$-71M$-2.75—
Dec 2021$-49M$10M$-59M$-4.17—
Dec 2020$-3M$4M$-7M$-28.52—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$5M
Net income, trailing 12 months
$-115M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-36M$1MDec ’24Three months to Mar 2025: revenue $2M, net income $-34M$2MMar ’25Three months to Jun 2025: revenue $3M, net income $-37M$3MJun ’25Three months to Sep 2025: revenue $3M, net income $-36M$3MSep ’25Three months to Dec 2025 (from the annual report): revenue $3M, net income $-23M$3MDec ’25Three months to Mar 2026: revenue $1M, net income $-29M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-30M$1MJun ’26Three months to Sep 2026: revenue $1M, net income $-33M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (-76.5% on a year earlier), net income $-33M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of TScan Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$10 M
Operating income
$-136 M
Net income
$-130 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$229 M
Total liabilities
$106 M
Total equity
$123 M

As of December-2025

Top 52 institutional investors in TScan Therapeutics, Inc.#

As of Sep 30, 2026
52 institutions held 32.7 M shares (about 48.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 42.3%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in TScan Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Lynx1 Capital Management LP8,019,1480 (0.00%)11.83%$3 MNov 16, 2026
2BVF Inc/il5,564,2900 (0.00%)8.21%$2 MNov 16, 2026
3Boothbay Fund Management, LLC3,400,092+2,627,851 (+340.29%)5.01%$1 MNov 16, 2026
4Baker Bros. Advisors LP2,784,7920 (0.00%)4.11%$1 MNov 16, 2026
5Vanguard Capital Management LLC2,508,887+350,056 (+16.22%)3.70%$1 MNov 13, 2026
6Acadian Asset Management LLC1,692,467+386,627 (+29.61%)2.50%$1 MNov 9, 2026
7Two Sigma Investments, LP1,644,246-305,358 (-15.66%)2.43%$1 MNov 16, 2026
8Deer Management Co. LLC1,245,5040 (0.00%)1.84%$0 MNov 16, 2026
9Renaissance Technologies LLC1,208,199-118,600 (-8.94%)1.78%$0 MNov 12, 2026
10DC Funds, LP630,0000 (0.00%)0.93%$0 MNov 13, 2026
11Geode Capital Management, LLC604,332+19,521 (+3.34%)0.89%$0 MNov 6, 2026
12BlackRock, Inc.597,865-396,789 (-39.89%)0.88%$0 MNov 13, 2026
13Gsa Capital Partners LLP510,700-37,387 (-6.82%)0.75%$0 MNov 16, 2026
14Vanguard Fiduciary Trust Co363,9540 (0.00%)0.54%$0 MNov 13, 2026
15Marshall Wace, LLP269,613-417,751 (-60.78%)0.40%$0 MNov 13, 2026
16Verdad Advisers, LP227,259-5,500 (-2.36%)0.34%$0 MNov 16, 2026
17State Street Corp206,600-713 (-0.34%)0.30%$0 MNov 12, 2026
18Northern Trust Corp138,7780 (0.00%)0.20%$0 MNov 16, 2026
19UBS Group AG108,247+39,374 (+57.17%)0.16%$0 MNov 10, 2026
20Morgan Stanley104,749-93,142 (-47.07%)0.15%$0 MNov 13, 2026
21Letko, Brosseau & Associates Inc95,8750 (0.00%)0.14%$0 MNov 6, 2026
22XTX Topco Ltd95,163-54,304 (-36.33%)0.14%$0 MNov 16, 2026
23Jane Street Group, LLC90,185-151,308 (-62.66%)0.13%$0 MNov 12, 2026
24Bridgeway Capital Management, LLC75,707-1,193 (-1.55%)0.11%$0 MNov 16, 2026
25Empowered Funds, LLC69,207New0.10%$0 MNov 13, 2026
Show all 52: investors 26 to 52
Institutional investors 26 to 52 in TScan Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26HRT Financial LP62,643-101,958 (-61.94%)0.09%$0 MNov 13, 2026
27Kestra Advisory Services, LLC62,5250 (0.00%)0.09%$0 MNov 2, 2026
28Goldman Sachs Group Inc59,672-10,842 (-15.38%)0.09%$0 MNov 16, 2026
29Citadel Advisors LLC51,756-957,351 (-94.87%)0.08%$0 MNov 16, 2026
30Bank Of America Corp /de/37,624-11,476 (-23.37%)0.06%$0 MNov 16, 2026
31DC Investments Management, LLC35,5630 (0.00%)0.05%$0 MNov 13, 2026
32HSBC Holdings PLC24,5740 (0.00%)0.04%$0 MNov 16, 2026
33R Squared Ltd21,607+3,247 (+17.69%)0.03%$0 MNov 6, 2026
34Barclays PLC17,081-2,089 (-10.90%)0.03%$0 MNov 6, 2026
35Vanguard Global Advisers, LLC15,7050 (0.00%)0.02%$0 MNov 13, 2026
36Two Sigma Securities, LLC14,054New0.02%$0 MNov 16, 2026
37AQR Capital Management LLC13,866New0.02%$0 MNov 16, 2026
38Ieq Capital, LLC13,723New0.02%$0 MNov 10, 2026
39Aries Wealth Management10,0000 (0.00%)0.01%$0 MOct 23, 2026
40Global Retirement Partners, LLC10,0000 (0.00%)0.01%$0 MNov 10, 2026
41Pathstone Holdings, LLC10,000New0.01%$0 MNov 13, 2026
42Osaic Holdings, Inc.9,756-2,489 (-20.33%)0.01%$0 MNov 12, 2026
43Tower Research Capital LLC (TRC)3,955+1,406 (+55.16%)0.01%$0 MNov 16, 2026
44Federated Hermes, Inc.3,497-485 (-12.18%)0.01%$0 MNov 12, 2026
45FMR LLC2,000+600 (+42.86%)0.00%$0 MNov 10, 2026
46Jpmorgan Chase & Co1,715-14,743 (-89.58%)0.00%$0 MNov 12, 2026
47BNP Paribas Financial Markets595-118 (-16.55%)0.00%$0 MNov 12, 2026
48SBI Securities Co., Ltd.391-1 (-0.26%)0.00%$0 MOct 22, 2026
49Strategic Wealth Partners, Ltd.3110 (0.00%)0.00%$0 MNov 13, 2026
50Royal Bank Of Canada87+9 (+11.54%)0.00%$0 MNov 16, 2026
51Root Financial Partners, LLC85New0.00%$0 MOct 21, 2026
52Caitong International Asset Management Co., Ltd10 (0.00%)0.00%$0 MOct 29, 2026

Mutual funds holding TScan Therapeutics, Inc.#

21 funds hold shares worth $4 M (about 4.8% of the company). Since their previous reports 10 added shares and 9 sold, selling $1 M net.
Mutual funds holding TScan Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.50 M$1 M2.0%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.575,570$1 M0.78%<0.01%−0.3%Jun 30, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC405,905$0 M0.55%0.04%−0.3%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC293,642$0 M0.40%<0.01%+8.2%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors167,533$0 M0.23%0.01%+44%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC87,566$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC72,914$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I69,487$0 M0.09%<0.01%newMay 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC70,400$0 M0.09%0.05%−33%Jun 30, 2026
🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC65,813$0 M0.09%<0.01%+67%Jun 30, 2026
🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS44,500$0 M0.06%<0.01%+33%Jun 30, 2026
🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS39,000$0 M0.05%0.02%+36%Jun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC29,612$0 M0.04%<0.01%+2368%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC28,767$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.29,605$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.19,320$0 M0.03%<0.01%−59%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC12,000$0 M0.02%<0.01%+69%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC11,250$0 M0.02%<0.01%+42%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC3,238$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.713$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC303$0 M<0.01%<0.01%+13%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 21 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at TScan Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$146 K
3 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$146 K
open market only
Insiders on file
11
since
$3.1 M-$952 K$0Dec 2023: bought $168 K (3 trades), sold $0 (0 trades)Dec 23Aug 2024: bought $56 K (2 trades), sold $952 K (1 trades)AugSep 2024: bought $26 K (1 trades), sold $0 (0 trades)SepNov 2024: bought $4 K (1 trades), sold $0 (0 trades)NovDec 2024: bought $386 K (2 trades), sold $0 (0 trades)DecMay 2025: bought $3.1 M (2 trades), sold $0 (0 trades)MayDec 2025: bought $146 K (3 trades), sold $0 (0 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
TScan Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Zoran ZdraveskiSee RemarksGrant or award+300,000——304,716Form 4
filed Gavin MacBeathChief Executive Officer, DirectorGrant or award+1.00 M——1.05 MForm 4
filed Lynx1 Capital Management LP10% ownerBuyindirect+6,232$0.900$6 K8.02 MForm 4
filed Lynx1 Capital Management LP10% ownerBuyindirect+75,500$0.900$68 K8.01 MForm 4
filed Lynx1 Capital Management LP10% ownerBuyindirect+80,069$0.900$72 K7.94 MForm 4
filed Lynx1 Capital Management LP10% ownerBuyindirect+1.20 M$1.200$1.4 M7.95 MForm 4
filed Lynx1 Capital Management LP10% ownerBuyindirect+1.39 M$1.200$1.7 M6.75 MForm 4
filed Weston Nichols10% ownerBuyindirect+100,000$2.900$290 K5.36 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: TScan Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.0 M
4.67 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 8.2-for-1 split

Fails to deliver

  • : 5,562 shares at $0.20
  • : 2,526 shares at $0.20
  • : 8,909 shares at $0.22
  • : 1,951 shares at $0.22
  • : 7,835 shares at $0.21

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

TScan Therapeutics, Inc. scorecard#

Passes 6 of the 19 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.1×Price to book 0.1× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median2.6×Price to sales 2.6× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 5
    • ✓Revenue grew in the newest year266.0%Revenue up 266.0% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-8.7%-8.7% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-8.7%-8.7% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.00 vs -1.14Diluted EPS -1.00 in fiscal 2025 against -1.14 the year before (report's currency).
    • ✗Net income higher than five years earlier-$130 M-$130 M in fiscal 2025 against -$26 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$130 MNet income -$130 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-71.3%-71.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 6
    • ✓Short-term assets cover short-term liabilities8.4×Current ratio 8.41 at the end of fiscal 2025.
    • ✓Debt below equity0.3×Debt to equity 0.26 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $120 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-49.0×Operating income -49.0 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-4.20Z-score -4.20 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year15.9%Diluted shares up 15.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from TScan Therapeutics, Inc.'s statements, beside the median of Biotechnology.

TScan Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Return on equity-71.3%-61.0%
Revenue growth, 3 years a year-8.7%12.9%
Revenue growth266.0%15.8%
Debt to equity0.26×0.26×

2of 8on the Piotroski tests of financial strength

  • Net loss of $130 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$140 million.
  • The share count rose 15.9% in the year.
  • Operating income covers the interest bill only -49.0 times.

TScan Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

TScan Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue102.82114101.1
Research and development11410788604521
General and administrative32302620146.7
Operating expenses146138115805927
Operating income−136−135−93−67−49−26
Interest expense and finance costs2.83.73.81.2——
Other non-operating income (expense)6.07.34.20.40.0—
Income tax0—————
Net income including minority interests−130−127−89−66−49−26
Net income attributable to shareholders−130−127−89−66−49−26
Earnings per share, basic-1.00-1.14-1.36-2.75-4.17-28.52
Earnings per share, diluted-1.00-1.14-1.36-2.75-4.17-28.52
Shares, weighted average (basic)130112662412—
Shares, weighted average (diluted)1301126624120.9
Balance sheet
Cash and cash equivalents15217913312016135
Short-term investments—11159———
Other current assets4.82.62.24.14.21.7
Current assets15729319412416636
Property, plant and equipment8.77.27.710125.7
Right-of-use (leased) assets586463595.56.9
Total assets22937127219918850
Accounts payable1.24.32.42.91.82.9
Debt due within a year——3.3———
Current liabilities193630172117
Long-term debt33322729——
Lease liabilities (non-current)546159534.46.0
Total liabilities1061301211002733
Retained earnings−505−375−248−158−92−44
Shareholders' equity12324115199161−42
Total liabilities and equity22937127219918850
Shares outstanding—————1.1
Cash-flow statement
Depreciation and amortization2.94.15.45.13.31.2
Share-based compensation129.55.24.62.50.5
Cash from operating activities−135−111−61−67−49−3.0
Capital expenditure−4.4−3.8−3.1−4.2−9.9−4.2
Cash from investing activities109−53−61−4.2−9.9−4.2
Debt issued———29——
Shares issued—33420.2——
Cash from financing activities−0.3209135291900.3
Change in cash−264513−41131−7.0
Report10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What TScan Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable$10 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at TScan Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Restructuring 2 · Directors and officers 7 · Material agreement 3 · Agreement ended 2 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9

TScan Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Delisting noticeRestructuringDirectors and officers8-K
Agreement ended8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Restructuring8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Material agreementAgreement endedNew debt8-K
Unregistered share sale8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of TScan Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2021$100 MNo. 2$50 to $250 million16equitySEC
Jul 2019$23 MNo. 1$10 to $50 million9equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at TScan Therapeutics, Inc.#

16 labor condition applications certified in fiscal 2026 for 16 positions, at a median wage of $104 K a year.

Certified, FY2026
16
#671 among companies on value.today
Worker positions
16
Median wage offered
$104 K
a year, full-time
Applications filed
16
TScan Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Principal Research AssociateMolecular and Cellular Biologists3$105 K
Senior Research AssociateBiochemists and Biophysicists3$75 K
Director, Pharmacovigilance OperationsRegulatory Affairs Managers1$225 K
Manufacturing Associate IIBioengineers and Biomedical Engineers1$103 K
Principal Computational Research AssociateBioinformatics Scientists1$105 K
Principal¿Research¿ScientistMolecular and Cellular Biologists1$95 K
Senior Research Associate, Preclinical DevelopmentMolecular and Cellular Biologists1$87 K
Senior Research Associate, Viral Vector & Discovery PlatformMolecular and Cellular Biologists1$92 K
Senior Supply Chain PlannerLogistics Analysts1$130 K
Sr. Associate, Regulatory AffairsRegulatory Affairs Specialists1$90 K

Where: Waltham, MA 16

TScan Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY20261616$104 K16
FY202599$105 K9
FY202444$75 K5
FY202322$88 K3
FY202222$85 K2
FY202011$130 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as TScan Therapeutics, Inc.

Layoffs at TScan Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
66
2025–2026
Latest
—
2026-08-27
TScan Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
2025··········66·66
TScan Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
75% of workforceRestructuring planSEC 8-K“Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 75% of the Company’s workforce (the “Strategic Reorganization”).”Filing
66 people (30% of workforce)Restructuring planSEC 8-K“Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 30% of the Company’s workforce, or 66 roles.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How TScan Therapeutics, Inc. compares in Biotechnology

  • Market cap$14 M · higher than 13% of 726
  • Revenue$10 M · higher than 44% of 647
  • Revenue growth266.0% · higher than 91% of 438
  • Price / sales2.6× · lower than 80% of 339
  • Price / book0.1× · lowest of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
TScan Therapeutics, Inc.🇺🇸$14 M——+266.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of February 27, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at TScan Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show TScan Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about TScan Therapeutics, Inc.? Suggest a correction